Milind Deshpande

Milind Deshpande, PhD, is a distinguished leader in the biotechnology sector with extensive experience spanning several high-impact roles. Currently serving as a Venture Partner at RA Capital Management, LLC since October 2018, and as Chairman of the Board and Founding CEO at Avilar Therapeutics, Deshpande has played pivotal roles in the development of innovative therapies targeting multi-drug resistant bacterial infections. As a co-founder and board member of Spero Therapeutics, Deshpande contributed to advancing a unique pipeline focused on unmet patient needs. Deshpande's earlier leadership as President and CEO of Achillion Pharmaceuticals emphasized the development of therapies for Hepatitis C and rare diseases, showcasing a strong track record of success in both organic and inorganic growth strategies. With a foundation in chemistry from Ohio University and significant research experience at Bristol-Myers Squibb and Boston University School of Medicine, Deshpande is recognized for contributions leading to the approval of Daclatasvir, a breakthrough treatment for Hepatitis C.